Alumis Stock Soars 17.5% on Japanese Licensing Deal

On March 26, 2025, Alumis' stock surged by 17.5% in pre-market trading, driven by a significant licensing agreement.

Alumis has entered into a licensing agreement with a Japanese partner to develop, manufacture, and commercialize an experimental skin drug. This deal is expected to bolster the company's presence in the Japanese market and enhance its product portfolio.

The collaboration focuses on ESK-001, an innovative drug aimed at addressing dermatological conditions. This strategic move is anticipated to strengthen Alumis' market position and drive future growth.